Thrombocytopenia: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
Robert P. Wise(Center for Biologics Evaluation and Research), Frederick Varricchio(Rutgers, The State University of New Jersey), Marianne Riise-Bergsaker(Norwegian Institute of Public Health), Jan Bonhoeffer(University Children’s Hospital Basel), Vitali Pool, Hugo Donato, Peter Downie(Monash Children’s Hospital), Dana C. Matthews(Fred Hutch Cancer Center), Terhi Tapiainen(Baylor College of Medicine), Judy A. Beeler(Center for Biologics Evaluation and Research)
Cited by 37
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
|PubMed|2003|397
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System
|The Pediatric Infectious Disease Journal|2004|381